The Technical AnalystExchange: OTC Sector: Healthcare Industry: Biotechnology
Clinuvel Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.99% $10.00
America/New_York / 3 mai 2024 @ 15:25
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 500.79 mill |
| EPS: | 0.370 |
| P/E: | 27.01 |
| Earnings Date: | Feb 22, 2024 |
| SharesOutstanding: | 50.10 mill |
| Avg Daily Volume: | 0.0042 mill |
| RATING 2024-05-03 |
|---|
| A+ |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.93x |
| Company: PE 27.01 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.20x |
| Company: PE 27.01 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$21.78 (117.88%) $11.78 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
$ 9.61 - 10.37 ( +/- 3.81%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $10.00 (1.99% ) |
| Volume | 0.0005 mill |
| Avg. Vol. | 0.0042 mill |
| % of Avg. Vol | 12.01 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CLVLY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CLVLY
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Latest Press Releases
Latest News
